|
1
|
Gastrointestinal Tumor Study Group.
Adjuvant therapy for colon cancer: results of a prospectively
randomized trial. N Engl J Med. 310:737–740. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mulcahy HE, Toner M, Patchett SE, et al:
Identifying stage B colorectal cancer patients at high risk of
tumor recurrence and death. Dis Colon Rectum. 40:326–336. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moertel CG: Chemotherapy of
gastrointestinal cancer. Recent Advances in Cancer Treatment.
Tajnon HJ and Staquet MJ: New York: Raven Press; pp. 311–323.
1997
|
|
4
|
Wolmark N, Rockette H, Fisher B, et al:
The benefit of leucovorin-modulated fluorouracil as postoperative
adjuvant therapy for primary colon cancer: results from National
Surgical Adjuvant Breast and Bowel Project. Protocol C-03. J Clin
Oncol. 11:1879–87. 1993.
|
|
5
|
Francini GP and Lorenzini L: Folinic acid
and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
Gastroenterology. 106:899–906. 1994.PubMed/NCBI
|
|
6
|
De Gramont A, Vignoud J, Tournigand C, et
al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil
48-hour continuous infusion in pretreated metastatic colorectal
cancer. Eur J Cancer. 33:214–219. 1997.
|
|
7
|
Rougier P, Van Cutsem E, Bajetta E, et al:
Randomised trial of irinotecan versus fluorouracil by continuous
infusion after fluorouracil failure in patients with metastatic
colorectal cancer. Lancet. 352:1407–1412. 1998. View Article : Google Scholar
|
|
8
|
Sargent DJ, Niedzwiecki D, O’ Conell MJ,
et al: Recommendation for caution with irinotecan, fluorouracil,
and leucovorin for colorectal cancer. N Engl J Med. 345:144–145.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
10
|
Scheithauer W, Kornek GV, Raderer M, et
al: Combined irinotecan and oxaliplatin plus granulocyte
colony-stimulating factor in patients with advanced
fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin
Oncol. 17:902–906. 1999.
|
|
11
|
Rothenberg ML: Efficiacy of oxaliplatin in
the treatment of colorectal cancer. Oncology. 14:9–14.
2000.PubMed/NCBI
|
|
12
|
Souglakos J, Mavroudis D, Kakolyris S, et
al: Triplet combination with irinotecan plus oxaliplatin plus
continuous-infusion fluorouracil and leucovorin as first-line
treatment in metastatic colorectal cancer: a multicenter phase II
trial. J Clin Oncol. 20:2651–2657. 2002. View Article : Google Scholar
|
|
13
|
Scheithauer W, Kornek GV, Raderer M, et
al: Randomized multicenter Phase II trial of two different
schedules of capecitabine plus oxaliplatin as first-line treatment
in advanced colorectal cancer. J Clin Oncol. 21:1307–1312. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan and oxaliplatin combinations in patients with previously
untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30.
2004. View Article : Google Scholar
|
|
15
|
Stathopoulos GP, Rigatos SK, Stathopoulos
JG, Xynotroulas JP and Dimou E: Efficacy and tolerability of
oxaliplatin plus irinotecan 5-fluorouracil and leucovorin regimen
in advanced stage colorectal cancer patients pretreated with
irinotecan, 5-fluorouracil and leucovorin. AJ Clin Oncol.
28:565–569. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stathopoulos GP, Rigatos SK, Malamos N, et
al: Long term survival of patients with advanced colorectal cancer
may not be due to the response to chemotherapy. Oncology Rep.
12:1295–1300. 2004.PubMed/NCBI
|
|
17
|
Therasse P, Arbuck SG, Eisenhower E, et
al: New guidelines to evaluate the response to tumor in solid
tumors. JNCI. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cunningham D, Pyrhonen S, James RD, et al:
Randomised trial of irinotecan plus supportive care versus
supportive care alone after fluorouracil failure for patients with
metastatic colorectal cancer. Lancet. 31(353): 1275–1276.
1999.PubMed/NCBI
|
